Female 0 6 0 6 B-gender
subjects 7 15 7 15 I-gender
who 16 19 16 19 O
are 20 23 20 23 O
pregnant 24 32 24 32 B-pregnancy

Human 0 5 33 38 B-chronic_disease
immunodeficiency 6 22 39 55 I-chronic_disease
virus 23 28 56 61 I-chronic_disease
( 29 30 62 63 I-chronic_disease
HIV)-positive 30 43 63 76 I-chronic_disease
subjects 44 52 77 85 O
on 53 55 86 88 O
combination 56 67 89 100 O
antiretroviral 68 82 101 115 B-treatment
therapy 83 90 116 123 I-treatment

Subjects 0 8 124 132 O
must 9 13 133 137 O
be 14 16 138 140 O
undergoing 17 27 141 151 O
autologous 28 38 152 162 B-treatment
or 39 41 163 165 I-treatment
allogeneic 42 52 166 176 I-treatment
hematopoietic 53 66 177 190 I-treatment
cell 67 71 191 195 I-treatment
transplant 72 82 196 206 I-treatment
( 83 84 207 208 I-treatment
HSCT 84 88 208 212 I-treatment
) 88 89 212 213 I-treatment
with 90 94 214 218 O
the 95 98 219 222 O
BEAM 99 103 223 227 O
conditioning 104 116 228 240 O
regimen 117 124 241 248 O
prior 125 130 249 254 O
to 131 133 255 257 O
HSCT 134 138 258 262 O

Subjects 0 8 263 271 O
unable 9 15 272 278 O
to 16 18 279 281 O
discontinue 19 30 282 293 O
benzodiazepines 31 46 294 309 B-treatment
will 47 51 310 314 O
not 52 55 315 318 O
be 56 58 319 321 O
allowed 59 66 322 329 O
as 67 69 330 332 O
hypnotics 70 79 333 342 B-treatment

Subjects 0 8 343 351 O
who 9 12 352 355 O
are 13 16 356 359 O
receiving 17 26 360 369 O
any 27 30 370 373 O
other 31 36 374 379 O
investigational 37 52 380 395 O
agents 53 59 396 402 O
or 60 62 403 405 O
have 63 67 406 410 O
received 68 76 411 419 O
another 77 84 420 427 O
investigational 85 100 428 443 O
drug 101 105 444 448 O
in 106 108 449 451 O
the 109 112 452 455 O
last 113 117 456 460 B-upper_bound
30 118 120 461 463 I-upper_bound
days 121 125 464 468 I-upper_bound

Subjects 0 8 469 477 O
who 9 12 478 481 O
have 13 17 482 486 O
a 18 19 487 488 O
serum 20 25 489 494 B-clinical_variable
creatinine 26 36 495 505 I-clinical_variable
> 37 38 506 507 O
2 39 40 508 509 B-lower_bound
x 41 42 510 511 I-lower_bound
upper 43 48 512 517 I-lower_bound
limit 49 54 518 523 I-lower_bound
of 55 57 524 526 I-lower_bound
normal 58 64 527 533 I-lower_bound
( 65 66 534 535 I-lower_bound
ULN 66 69 535 538 I-lower_bound
) 69 70 538 539 I-lower_bound

Subjects 0 8 540 548 O
who 9 12 549 552 O
have 13 17 553 557 O
been 18 22 558 562 O
drinking 23 31 563 571 O
> 32 33 572 573 O
5 34 35 574 575 B-lower_bound
alcoholic 36 45 576 585 O
drinks 46 52 586 592 O
daily 53 58 593 598 O
for 59 62 599 602 O
the 63 66 603 606 O
last 67 71 607 611 O
year 72 76 612 616 O

Subjects 0 8 617 625 O
who 9 12 626 629 O
have 13 17 630 634 O
concurrent 18 28 635 645 O
illness 29 36 646 653 O
requiring 37 46 654 663 O
systemic 47 55 664 672 B-treatment
corticosteroid 56 70 673 687 I-treatment
use 71 74 688 691 O

Subjects 0 8 692 700 O
who 9 12 701 704 O
have 13 17 705 709 O
had 18 21 710 713 O
emesis 22 28 714 720 O
or 29 31 721 723 O
required 32 40 724 732 O
antiemetics 41 52 733 744 B-treatment
in 53 55 745 747 O
the 56 59 748 751 O
48 60 62 752 754 B-upper_bound
hours 63 68 755 760 I-upper_bound
prior 69 74 761 766 I-upper_bound
to 75 77 767 769 O
starting 78 86 770 778 O
the 87 90 779 782 O
BEAM 91 95 783 787 B-treatment
conditioning 96 108 788 800 I-treatment
regimen 109 116 801 808 I-treatment

Subjects 0 8 809 817 O
who 9 12 818 821 O
have 13 17 822 826 O
taken 18 23 827 832 O
a 24 25 833 834 O
neurokinin 26 36 835 845 B-treatment
antagonist 37 47 846 856 I-treatment
within 48 54 857 863 O
14 55 57 864 866 B-upper_bound
days 58 62 867 871 I-upper_bound
prior 63 68 872 877 I-upper_bound
to 69 71 878 880 O
beginning 72 81 881 890 O
the 82 85 891 894 O
BEAM 86 90 895 899 B-treatment
regimen 91 98 900 907 I-treatment

Subjects 0 8 908 916 O
with 9 13 917 921 O
a 14 15 922 923 O
history 16 23 924 931 O
of 24 26 932 934 O
anxiety 27 34 935 942 B-chronic_disease
- 34 35 942 943 I-chronic_disease
induced 35 42 943 950 I-chronic_disease
( 43 44 951 952 I-chronic_disease
anticipatory 44 56 952 964 I-chronic_disease
) 56 57 964 965 I-chronic_disease
nausea 58 64 966 972 O
and 65 68 973 976 O
vomiting 69 77 977 985 O

Subjects 0 8 986 994 O
with 9 13 995 999 O
gastrointestinal 14 30 1000 1016 B-chronic_disease
conditions 31 41 1017 1027 I-chronic_disease
which 42 47 1028 1033 O
might 48 53 1034 1039 O
result 54 60 1040 1046 O
in 61 63 1047 1049 O
malabsorption 64 77 1050 1063 B-chronic_disease
of 78 80 1064 1066 O
the 81 84 1067 1070 O
study 85 90 1071 1076 O
drug 91 95 1077 1081 O

Subjects 0 8 1082 1090 O
with 9 13 1091 1095 O
known 14 19 1096 1101 O
hypersensitivity 20 36 1102 1118 O
or 37 39 1119 1121 O
other 40 45 1122 1127 O
allergic 46 54 1128 1136 O
reactions 55 64 1137 1146 O
attributed 65 75 1147 1157 O
to 76 78 1158 1160 O
compounds 79 88 1161 1170 O
of 89 91 1171 1173 O
similar 92 99 1174 1181 O
biologic 100 108 1182 1190 O
composition 109 120 1191 1202 O
to 121 123 1203 1205 O
netupitant 124 134 1206 1216 B-allergy_name
, 134 135 1216 1217 O
palonosetron 136 148 1218 1230 B-allergy_name
, 148 149 1230 1231 O
dexamethasone 150 163 1232 1245 B-allergy_name
, 163 164 1245 1246 O
or 165 167 1247 1249 O
other 168 173 1250 1255 O
agents 174 180 1256 1262 O
used 181 185 1263 1267 O
in 186 188 1268 1270 O
the 189 192 1271 1274 O
study 193 198 1275 1280 O

Subjects 0 8 1281 1289 O
with 9 13 1290 1294 O
personal 14 22 1295 1303 O
or 23 25 1304 1306 O
family 26 32 1307 1313 O
history 33 40 1314 1321 O
of 41 43 1322 1324 O
QT 44 46 1325 1327 B-chronic_disease
prolongation 47 59 1328 1340 I-chronic_disease

Subjects 0 8 1341 1349 O
with 9 13 1350 1354 O
severe 14 20 1355 1361 B-chronic_disease
renal 21 26 1362 1367 I-chronic_disease
failure 27 34 1368 1375 I-chronic_disease
or 35 37 1376 1378 O
end 38 41 1379 1382 B-chronic_disease
stage 42 47 1383 1388 I-chronic_disease
renal 48 53 1389 1394 I-chronic_disease
disease 54 61 1395 1402 I-chronic_disease
( 62 63 1403 1404 O
estimated 63 72 1404 1413 B-clinical_variable
GFR 73 76 1414 1417 I-clinical_variable
[ 77 78 1418 1419 I-clinical_variable
glomerular 78 88 1419 1429 I-clinical_variable
filtration 89 99 1430 1440 I-clinical_variable
rate 100 104 1441 1445 I-clinical_variable
] 104 105 1445 1446 I-clinical_variable
of 106 108 1447 1449 O
< 109 110 1450 1451 O
30 111 113 1452 1454 B-upper_bound
mL 114 116 1455 1457 I-upper_bound
/ 116 117 1457 1458 I-upper_bound
min 117 120 1458 1461 I-upper_bound
) 120 121 1461 1462 O
as 122 124 1463 1465 O
estimated 125 134 1466 1475 O
by 135 137 1476 1478 O
the 138 141 1479 1482 O
Cockcroft 142 151 1483 1492 O
- 151 152 1492 1493 O
Gault 152 157 1493 1498 O
formula 158 165 1499 1506 O

antiemetics 0 11 1507 1518 B-treatment
will 12 16 1519 1523 O
be 17 19 1524 1526 O
allowed 20 27 1527 1534 O
for 28 31 1535 1538 O
rescue 32 38 1539 1545 O
but 39 42 1546 1549 O
not 43 46 1550 1553 O
for 47 50 1554 1557 O
prophylaxis 51 62 1558 1569 B-treatment

pregnant 0 8 1570 1578 B-pregnancy
women 9 14 1579 1584 B-gender
are 15 18 1585 1588 O
excluded 19 27 1589 1597 O
from 28 32 1598 1602 O
this 33 37 1603 1607 O
study 38 43 1608 1613 O

the 0 3 1614 1617 O
planned 4 11 1618 1625 O
dexamethasone 12 25 1626 1639 B-treatment
during 26 32 1640 1646 O
conditioning 33 45 1647 1659 B-treatment
therapy 46 53 1660 1667 I-treatment

uncorrected 0 11 1668 1679 O
electrolyte 12 23 1680 1691 B-chronic_disease
abnormalities 24 37 1692 1705 I-chronic_disease

